# Risk: __Lack of preexisting immunities__ (PBN__Risk_2109)

## Property: has_RiskSubject

* [general population](../Stakeholder/PBN__Stakeholder_9)

## Property: has_RiskISO_Impact

* [Community infrastructures](../RiskISO/PBN__RiskISO_Purpose_9)

## Property: has_RiskSource

* [sovacool_contextualizing_2020](../Article/PBN__Article_123)

## Property: has_RiskName

Higher susceptibility to infection and increased risk of severe symptoms

## Property: has_RiskHealth

* [physical](../RiskHealth/PBN__RiskHealth_0)

## Property: has_RiskGBN

* [Yes](../RiskGBN/PBN__RiskGBN_1)

## Property: has_RiskTechnology

* [vaccine development and distribution](../Technology/PBN__Technology_1604)

## Property: has_RiskOwner

* [healthcare institutions](../Stakeholder/PBN__Stakeholder_269)
* [pharmaceutical companies](../Stakeholder/PBN__Stakeholder_124)
* [governments](../Stakeholder/PBN__Stakeholder_47)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskDescription

Lack of immunity to Covid-19 in the general population

## Property: has_RiskISO_Purpose

* [Resilience](../RiskISO/PBN__RiskISO_Impact_2)

## Property: has_RiskMitigation

* [Develop vaccines and promote vaccination programs](../RiskMitigation/PBN__RiskMitigation_2759)

